Analysts Set Bicycle Therapeutics plc (NASDAQ:BCYC) Target Price at $33.25

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have received an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $33.25.

BCYC has been the topic of several recent research reports. Stephens reissued an “equal weight” rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. Finally, B. Riley cut their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th.

Bicycle Therapeutics Trading Down 2.1 %

Shares of NASDAQ BCYC opened at $12.61 on Tuesday. The company has a market cap of $870.72 million, a price-to-earnings ratio of -3.83 and a beta of 0.93. Bicycle Therapeutics has a 12-month low of $12.17 and a 12-month high of $28.67. The stock’s 50 day simple moving average is $15.38 and its 200 day simple moving average is $20.70.

Insider Activity

In related news, COO Alistair Milnes sold 4,578 shares of Bicycle Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $64,504.02. Following the transaction, the chief operating officer now directly owns 100,724 shares in the company, valued at $1,419,201.16. The trade was a 4.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,933 shares of company stock worth $549,501. 8.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Assetmark Inc. acquired a new stake in shares of Bicycle Therapeutics in the third quarter worth $34,000. GAMMA Investing LLC boosted its position in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after buying an additional 1,038 shares during the period. Avior Wealth Management LLC acquired a new stake in shares of Bicycle Therapeutics in the fourth quarter worth $57,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after buying an additional 2,191 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after buying an additional 1,782 shares during the period. 86.15% of the stock is currently owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.